Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (2): 285-288    DOI: 10.12891/ceog4948.2019
Case Report Previous articles | Next articles
Weekly vaginal administration of tamoxifen for three months in postmenopausal women with vulvar and vaginal atrophy: a possible new treatment approach?
J. Chollet1, *(), L. A. Meyn2, F. Mermelstein3
1Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, USA
2Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, USA
3Department of Neurobiology, Harvard Medical School, Boston, USA
Download:  PDF(201KB)  ( 80 ) Full text   ( 17 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

An exploratory study was conducted recruiting four healthy postmenopausal women suffering from vulvar and vaginal atrophy (VVA). Subjects self-administered vaginal suppositories containing tamoxifen (20 mg). Subjects were instructed to insert one suppository vaginally once daily for one week and twice weekly over a period of three months. Vaginal pH and dryness scores using a visual analog scale (VAS) were recorded at enrollment and subsequent assessments were recorded using self-assessment questionnaires over a three-month period. Serum tamoxifen levels were measured after two months of suppository use. After three months, both vaginal pH and vaginal dryness symptoms showed significant improvement. Vaginal pH scores improved approximately 30% compared to baseline by completion of the study. Vaginal dryness scores improved approximately 63% compared to baseline. As expected, serum tamoxifen levels were negligible ranging from 1.0 ng/ml to 10.0 ng/ml determined after eight weeks on the treatment. The present results suggest that delivery of tamoxifen directly to the vaginal epithelium for the treatment of VVA may be a viable new treatment approach. Therefore, this route of administration may offer an important treatment modality for patients with a history of breast cancer, at risk for breast cancer, and who have hormone-receptor-positive breast cancer, including estrogen receptor-positive (ER-positive), and progesterone receptor-positive (PR-positive) in addition to node negative breast cancer.

Key words:  Vulvar and vaginal atrophy      Tamoxifen      Vaginal pH      Vaginal dryness     
Published:  10 April 2019     
*Corresponding Author(s):  J. CHOLLET     E-mail:  jchollet@bidmc.harvard.edu

Cite this article: 

J. Chollet, L. A. Meyn, F. Mermelstein. Weekly vaginal administration of tamoxifen for three months in postmenopausal women with vulvar and vaginal atrophy: a possible new treatment approach?. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 285-288.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4948.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I2/285

[1] Zhongying Huang, Zhun Xiao, Qianhong Ma, Yu Bai, Feilang Li. Efficacy of tamoxifen for infertile women with thin endometrium undergoing frozen embryo transfer: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 806-811.
[2] S. Nayak, A. Avery, J. McLeod Griffiss, C.D. Charles, K.R. Culwell. A randomized placebo-controlled pilot study of the effect and duration of Amphora, a multipurpose vaginal pH regulator, on vaginal pH[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 736-742.
[3] D. Carati, A. Zizza, M. Guido, A. De Donno, R. Stefanizzi, R. Serra, I. Romano, C. Ouedraogo, M. Megha, A. Tinelli. Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(2): 198-202.
[4] Z. Basirat, S.H. Barat, A. Ghanbarpour, M. Golsorkhtabar-Amiri. Does vaginal pH affect the efficacy of dinoprostone in cervical ripening/labor duration?[J]. Clinical and Experimental Obstetrics & Gynecology, 2012, 39(4): 522-525.
[5] D.M. Rodrigues-Junior, P.V. Lopes-Costa, A.R. dos Santos, B.B. da Silva. Effects of tamoxifen and raloxifene on body and uterine weights of rats in persistent estrus[J]. Clinical and Experimental Obstetrics & Gynecology, 2012, 39(3): 362-364.
[6] M. Gharehbagni, F. Sendag, F. Akercan, B. Zeybek, E. Sezer, M.C. Terek, N. Karadadas. Effects of tamoxifen on tissue nitrite/nitrate levels and plasma lipid peroxidation in female rats[J]. Clinical and Experimental Obstetrics & Gynecology, 2010, 37(2): 112-114.
[7] I. D. C. Guerreiro Da Silva, E. Dias-Netto, F. E. Villanova, L. Yamamoto, E. C. Baracat, G. R. Lima, L. H. Gebrim. Tamoxifen down-regulates CaMKII messenger RNA levels in normal human breast tissue[J]. Clinical and Experimental Obstetrics & Gynecology, 2004, 31(3): 204-208.
[8] B. Borges da Silva, L. H. Gebrim, M. J. Simoes, E. C. Baracat, G. Rodrigues de Lima. Morphologic and morphometric study of the breast parenchyma of rats in persistent estrus treated with tamoxif en and conjugated estrogens[J]. Clinical and Experimental Obstetrics & Gynecology, 2001, 28(1): 60-62.
[9] P. M. Andrade, E. C. Baracat, M. J. Simões, G. Rodrigues de Lima. Histomorphometric aspects of adult castrated rat endometrium after the use of estrogen, progesterone and tamoxifen[J]. Clinical and Experimental Obstetrics & Gynecology, 2000, 27(2): 138-141.
[10] M. Friedrich, D. Mink, C. Villena-Heinsen, A. Woll-Hermann, S. Wagner, W. Schmidt. The influence of tamoxifen on the maturation index of vaginal epithelium[J]. Clinical and Experimental Obstetrics & Gynecology, 1998, 25(4): 121-124.
[11] E. Deveci, A. Onen, O. Tacar, A. Yildirim. The effect of tamoxif en on the neonatal development of rat glans penis[J]. Clinical and Experimental Obstetrics & Gynecology, 1997, 24(4): 237-239.
[12] P. LITTA, A. AZZENA, A. SANDRI, C. VASILE. Hysteroscopic follow-up in Tamoxifen treatment for breast cancer[J]. Clinical and Experimental Obstetrics & Gynecology, 1995, 22(1): 47-50.
[13] A. Re, T. Wierdis, M. Tessarolo, L. Leo, R. Bellino, A. Lauricella, A. LANZA. Two cases of ovarian cysts in postmenopausal patients under antiestrogen treatment[J]. Clinical and Experimental Obstetrics & Gynecology, 1994, 21(4): 221-224.
[14] L. LEO, A. LANZA, A. RE, M. TESSAROLO, R. BELLINO, A. LAURICELLA, T. WIERDIS. Leiomyomas in patients receiving Tamoxifen[J]. Clinical and Experimental Obstetrics & Gynecology, 1994, 21(2): 94-98.
[15] S. Rullo, T. Tagliaferri, F. Bandiera, C. Fiorelli, A. Felici, M. G. Piccioni, M. L. Framarino dei Malatesta. Uterine changes during Tamoxifen therapy[J]. Clinical and Experimental Obstetrics & Gynecology, 1993, 20(2): 116-119.
No Suggested Reading articles found!